Investigation of factors that may influence the course of a SARS-CoV-2 infection (COVID-19): A study of the University Medical Center Greifswald

Investigation of factors that may influence the course of a SARS-CoV-2 infection (COVID-19): A study of the University Medical Center Greifswald - COVER-Studie

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00021672

Enrollment

400

Registered

2020-12-01

Start date

2020-04-30

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Group 1: Patients with positive SARS-CoV-2 infection are interviewed with a questionnaire about previous illnesses and the course of symptoms over 25 days after a positive test.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Individuals with a PCR-confirmed SARS-CoV-2 infection. This includes persons who have been examined in the test centers in Mecklenburg-Western Pomerania on an outpatient basis as well as inpatients admitted to Greifswald University Hospital or other participating hospitals.

Exclusion criteria

Exclusion criteria: Below 18 years of age

Design outcomes

Primary

Measure	Time frame
The primary outcome is the course of SARS-CoV-2 infection classified according to the WHO ladder as follows: score 1: Outpatient with mild course of infection; no limitation of patient activities; score 2: Outpatient with mild course of infection but with limited activities, no hospital admission necessary; score 3: Moderately course; hospitalized, no oxygen supply necessary; score 4: Moderately course; hospitalized, oxygen supply via oxygen mask or nasal cannula, score 5: Severe course; non-invasive ventilation or high-flow oxygen therapy; score 6: Severe course; intubation and invasive ventilation, score 7: Severe course; intubation and invasive ventilation + additional organ function support, renal replacement therapy, ECMO; score 8: Death; patient's death; The following parameters should be recorded in individuals who have tested positive for infection with the SARSCoV-2 virus - General information on the participating persons such as gender and age, as well as information on lifestyle, e.g. smoking - pre-existing conditions such as cardiovascular or oncological diseases, previous damage of the lung or liver, infections with other pathogens or colonization with multi-resistant pathogens and other pre-existing underlying diseases - Information on medication already taken before the illness - Information about the medication taken during the course of the disease, e.g. antipyretic preparations	—

Measure

Time frame

The primary outcome is the course of SARS-CoV-2 infection classified according to the WHO ladder as follows: score 1: Outpatient with mild course of infection; no limitation of patient activities; score 2: Outpatient with mild course of infection but with limited activities, no hospital admission necessary; score 3: Moderately course; hospitalized, no oxygen supply necessary; score 4: Moderately course; hospitalized, oxygen supply via oxygen mask or nasal cannula, score 5: Severe course; non-invasive ventilation or high-flow oxygen therapy; score 6: Severe course; intubation and invasive ventilation, score 7: Severe course; intubation and invasive ventilation + additional organ function support, renal replacement therapy, ECMO; score 8: Death; patient's death; The following parameters should be recorded in individuals who have tested positive for infection with the SARSCoV-2 virus - General information on the participating persons such as gender and age, as well as information on lifestyle, e.g. smoking - pre-existing conditions such as cardiovascular or oncological diseases, previous damage of the lung or liver, infections with other pathogens or colonization with multi-resistant pathogens and other pre-existing underlying diseases - Information on medication already taken before the illness - Information about the medication taken during the course of the disease, e.g. antipyretic preparations

—

Secondary

Measure	Time frame
As secondary endpoints are defined (i) descriptive analyses of the prevalence and duration of symptoms in outpatients and (ii) association analysis of the prevalence and duration of single symptoms with the risk and protective factors listed above.	—

Countries

Germany

Contacts

Public ContactEik Schäfer

Universitätsmedizin Greifswald Körperschaft des öffentlichen Rechts Institut für Pharmakologie

eik.schaefer@med.uni-greifswald.de03834 86 5659

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 6, 2026